Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tegavivint

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Iterion Announces First Patient Dosed in Phase 1b/2a Trial of Tegavivint
    Iterion Announces First Patient Dosed in Phase 1b/2a Trial of Tegavivint

    20 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-phase-1b2a-clinical-trial-of-tegavivint-in-patients-with-advanced-hepatocellular-carcinoma-who-have-failed-one-or-more-systemic-treatments-302065477.html

    PR NEWSWIRE
    20 Feb 2024
    Share Share
    Iterion Therapeutics Announces the Initiation of a Ph 1 Trial for Tegavivint
    Iterion Therapeutics Announces the Initiation of a Ph 1 Trial for Tegavivint

    16 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-the-initiation-of-a-phase-1-clinical-trial-for-tegavivint-in-patients-with-c-myc-overexpressing-relapsed-or-refractory-large-b-cell-lymphomas-301825538.html

    PR NEWSWIRE
    16 May 2023
    Share Share
    Iterion Tx Announces Results from PI Dose Escalation Study of Tegavivint
    Iterion Tx Announces Results from PI Dose Escalation Study of Tegavivint

    01 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-results-from-phase-1-dose-escalation-study-of-tegavivint-in-desmoid-tumors-to-be-presented-at-the-2022-asco-annual-meeting-301558729.html

    PRNEWSWIRE
    01 Jun 2022
    Share Share
    Iterion Tx to Present 3 Posters Involving Research into Tegavivint at AACR
    Iterion Tx to Present 3 Posters Involving Research into Tegavivint at AACR

    08 Apr 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-presentation-of-three-posters-involving-research-into-tegavivint-at-the-aacr-2022-annual-meeting-301520693.html

    PRNEWSWIRE
    08 Apr 2022
    Share Share
    Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers
    Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers

    10 Nov 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/iterion-phase-i-ii-trial-tegavivint-paediatric-cancers/

    CLINICALTRIALSARENA
    10 Nov 2021
    Share Share
    Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers
    Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers

    09 Nov 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/iterion-phase-i-ii-trial-tegavivint-paediatric-cancers/

    CLINICALTRIALSARENA
    09 Nov 2021
    Share Share